{"links":{"feed":"https://www.erudio.com/reports/parrc-nct06770582/feed.json","html":"https://www.erudio.com/reports/parrc-nct06770582","json":"https://www.erudio.com/reports/parrc-nct06770582.json","markdown":"https://www.erudio.com/reports/parrc-nct06770582.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"parrc-nct06770582"}},"request":"https://www.erudio.com/contact?report=parrc-nct06770582"},"offer":{"cited_clinicians":3,"cited_commentary_sources":6,"verified_hcp_statements":7,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":3},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"parrc-nct06770582"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=parrc-nct06770582","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/parrc-nct06770582","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 7 verified statements · 4 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T16:07:39.660385Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":4,"no_commentary_found":5},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Bladder intact event-free survival (BIEFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Global quality of life"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":0,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":2,"title":"Cystectomy versus consideration of chemoradiation"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Enrollment suggestion within a BCG-unresponsive CIS exchange"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":2,"cited_clinicians":3,"cited_clinicians_by_role":{"physician, Radiation oncology":2,"physician, Urology":1},"cited_physicians":3,"cited_sources":6,"claims_by_expression_type":{"opinion":4,"question":1,"restatement":2},"claims_by_kind":{"source_observation":7},"clinician_statements":4,"evidence_units":12,"findings":3,"organisational_accounts":2,"people_cited":3,"people_identity_verified":3,"people_total":4,"screened_sources":26,"verified_claims":7},"findings_index":[{"cited_clinicians":2,"id":"F2","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"limitations":3,"links":{"context":1,"support":2},"ma_question":true,"named_voices":2,"passages":3,"sources":2,"sources_by_kind":{"commentary":2}},"title":"PARRC: a clinician encourages opening and accrual; one welcomes activation","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-4bf01514f2e39d3897c9"],"clause":"one welcomes activation","holders":1},"cited_claim_ids":["claim-e4f1a21d67e80f73e31e"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"2 statements from 2 speakers in 2 sources","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one welcomes activation”"},{"cited_clinicians":1,"id":"F1","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":0},"limitations":4,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"BCG-unresponsive NMIBC: a clinician relays a question on chemoradiation vs cystectomy","title_holders":{"cited_claim_ids":["claim-a307bf9402ddfee2738c","claim-8a1c71cf60f55f2d147d"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F3","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":1},"limitations":1,"links":{"context":1,"support":3},"ma_question":true,"named_voices":1,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"BCG-unresponsive CIS: a clinician proposes enrollment in NRG GU014","title_holders":{"cited_claim_ids":["claim-495fe63f627165e72dbc"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 3 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"}],"open_question":{"basis":"From finding F1 (2 statements from 1 speaker in 2 sources)","cited_claim_ids":["claim-a307bf9402ddfee2738c","claim-8a1c71cf60f55f2d147d"],"finding_ids":["F1"],"question":"In PARRC’s setting of BCG-unresponsive high-grade T1 bladder cancer, could chemoradiation be considered instead of cystectomy?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One X account encourages participation; another welcomes activation"},{"id":"section-2","level":2,"title":"One X account relays an open cystectomy–chemoradiation question"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"One X account proposes enrollment within a CIS treatment exchange"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Bladder intact event-free survival (BIEFS)"},{"findings":[],"id":"T2","label":"Primary endpoint: Global quality of life"},{"findings":[],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[],"id":"T5","label":"The comparison"},{"findings":[],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F1","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T16:07:39.660385Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T16:18:42Z","record_hash":"fd062dc5456f1d0ab164089a0695facb8e348b40b2c672b975ab2182cf67f4c5","release_hash":"280dbd99fce2a08f66a8e44495127293d894aa6465b86f49fc4553abba353082","report_id":"erudio-nct06770582","run_id":"37d2570d-1e61-41fa-87b2-6c8c1e3c955a","schema_version":"5.0","slug":"parrc-nct06770582","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A radiation oncologist whose trial involvement is unconfirmed encouraged participation in PARRC; a urologist responded favorably to its launch. Neither comment expressed a treatment preference. The broader treatment context tentatively raised chemoradiation alongside a reported audience preference for cystectomy, relaying a presentation by a speaker described as a trial principal investigator. An enrollment suggestion in BCG-unresponsive CIS left eligibility unclear. The comments do not assess comparative benefit, safety or quality-of-life trade-offs.","examples":[],"meta_description":"26 sources screened · 7 verified statements (4 from clinicians verified by NPI or staff page) from 6 sources · 3 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T16:18:42Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":26},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on economic and patient-goal trade-offs in sequencing bladder-sparing treatments versus cystectomy.","21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 35 sources about other trials or topics are not included; discussion that uses 2 names the trial shares with other things, without the trial's condition or setting, may be missing.","Brief social-media statements provide little explanation of patient selection, treatment trade-offs or practical implementation; their strength should not be expanded into prescribing recommendations.","A reported audience preference and organizational repetition do not establish independent clinician consensus.","Discussion that did not name the trial or used different wording may be absent, so the report is not representative of all public or HCP discussion.","No full protocol or exact-trial results publication accompanies these views in the sources reviewed for this edition; the posts do not support a comprehensive appraisal of methods or outcomes.","The linked-article quotation about unmet need is incomplete and does not identify its speaker, so it cannot be assigned to a named clinician.","The enrollment suggestion made in the CIS exchange does not establish which patients would satisfy PARRC eligibility."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":6,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":6},"count":6,"evidence_window":{"end":"2026-08-28","start":"2025-02-14"},"retrieval_snapshot":"2026-11-21T15:06:35.607549Z","timeline":[{"count":2,"week":"2025-W07"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W35"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06770582:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06770582:context","quote_policy":"short_quote_link_out"},{"id":"openfda:93edf309-993c-48ec-be90-27d89c86b62b:20261112","quote_policy":"short_quote_link_out"},{"id":"openfda:1daf714b-704c-4bcc-b6e0-6f0eb2bfe66b:20261023","quote_policy":"short_quote_link_out"},{"id":"openfda:3aef8dbc-34d0-4150-89f0-3b16cf0fbfdb:20261026","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-3tcosqfcvofvwstehvqggkwj-3mlqjl5wdvr2z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ho5otbscl53wyxvkxd5soiyo-3lk22miuctk2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ho5otbscl53wyxvkxd5soiyo-3lngazwaokc26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ho5otbscl53wyxvkxd5soiyo-3mlvuci4q6m2g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ho5otbscl53wyxvkxd5soiyo-3mq7xaloydw2z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ho5otbscl53wyxvkxd5soiyo-3mu5htyzn5c2h","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1880339781525336140:e9da7084-174c-4859-937d-0c3ff38c8bee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1881743210843693199:ffac4f41-327f-4837-a830-9ea51a4c58e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890475692338368753:a12a0f63-e5ab-4eb7-933f-b164dcee559f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890774594648514900:20ff34e4-eb8d-432d-ba43-0d7eec4b62ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1899151626247500224:bd3a2e77-a8ba-4de2-b3ae-51829eef7ee1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1902450406619529245:2ea83cf9-6e57-4d1c-b62e-9ce82c4b6819","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1914694491795001647:a90fc9d6-8cf1-46ba-b392-fa25b6de56f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1948751303359770842:9d9cd180-b4b4-4ac7-baca-f4de6c82ff54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978168880603242695:c536aee2-1cd2-4f9b-b581-f166aaac8626","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2015083820979012052:567981c7-e294-4a38-bfd8-81e178ae4684","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2015090484222230653:4d0ecbea-acd6-4605-a1f7-79c00e9a4027","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2015092174967165329:a3df0dd2-b84a-4915-909a-528441416c9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2015092311072665766:ec62e4a7-6a20-40c3-8dcf-b4f81c113ea6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027460068866986157:dc83276d-9dc8-45ff-9c00-cb95bc587235","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2054571097278841329:ccd88315-d110-41e6-b88e-e6361d58f14d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055339991815844318:e5c50efc-bec2-4b39-9b20-afef5ee871f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075241132485759368:b412fb4a-e8f3-44ea-971a-b8e3c8c588ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093330321462665601:9da35337-8f1b-4b70-8bb1-34d252acebc3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097685503839502587:4a83c11e-6304-4c35-a1c2-d6c2ddc38c34","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:OfkXt66UUWc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":6,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":19,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":26},"count":26,"evidence_window":{"end":"2026-11-19","start":"2025-01-17"},"retrieval_snapshot":"2026-11-21T15:06:35.707114Z","timeline":[{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W04"},{"count":2,"week":"2025-W07"},{"count":2,"week":"2025-W11"},{"count":1,"week":"2025-W12"},{"count":2,"week":"2025-W17"},{"count":1,"week":"2025-W30"},{"count":1,"week":"2025-W42"},{"count":4,"week":"2026-W04"},{"count":1,"week":"2026-W09"},{"count":4,"week":"2026-W20"},{"count":2,"week":"2026-W28"},{"count":2,"week":"2026-W35"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W47"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Mitozytrex","Mutamycin","Zusduri"],"label":"mitomycin","slug":"mitomycin"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"reason":"Unmapped registry condition: Non-Muscle Invasive Bladder Urothelial Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Stage I Bladder Cancer AJCC v8","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Urothelial carcinoma","slug":"urothelial-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"PARRC","aliases":["PARRC","PARRC Trial","Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)"],"brief_title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Muscle Invasive Bladder Urothelial Carcinoma","Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma","Stage I Bladder Cancer AJCC v8"],"display_condition":"high-grade T1 bladder cancer","display_interventions":[["pembrolizumab"]],"enrollment":{"count":160,"type":"ESTIMATED"},"interventions":[{"name":"Biospecimen Collection","synonyms":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Cisplatin","synonyms":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Computed Tomography","synonyms":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Fluorouracil","synonyms":["5 Fluorouracil","5 Fluorouracilum","5 FU","5-Fluoro-2,4(1H, 3H)-pyrimidinedione","5-Fluorouracil","5-Fluracil","5-Fu","5FU","AccuSite","Carac","Fluoro Uracil","Fluouracil","Flurablastin","Fluracedyl","Fluracil","Fluril","Fluroblastin","Ribofluor","Ro 2-9757","Ro-2-9757"],"type":"DRUG"},{"name":"Gemcitabine","synonyms":["dFdC","dFdCyd","Difluorodeoxycytidine"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","synonyms":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Mitomycin","synonyms":["Ametycine","Jelmyto","MITO","Mito-C","Mito-Medac","Mitocin","Mitocin-C","Mitolem","Mitomycin C","Mitomycin pyelocalyceal","Mitomycin-C","Mitomycin-X","Mitomycine C","Mitosol","Mitozytrex","Mutamycin","Mutamycine","NCI-C04706"],"type":"DRUG"},{"name":"Pembrolizumab","synonyms":["BCD-201","GME 751","GME751","Keytruda","Lambrolizumab","MK 3475","MK-3475","MK3475","Pembrolizumab Biosimilar BCD-201","Pembrolizumab Biosimilar GME751","Pembrolizumab Biosimilar QL2107","Pembrolizumab Biosimilar RPH-075","Pembrolizumab Biosimilar SB27","QL2107","RPH 075","RPH-075","RPH075","SB 27","SB-27","SB27","SCH 900475","SCH-900475","SCH900475"],"type":"BIOLOGICAL"},{"name":"Questionnaire Administration","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"},{"name":"Radiation Therapy","synonyms":["Cancer Radiotherapy","Energy Type","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"],"type":"RADIATION"}],"nct_id":"NCT06770582","official_title":"Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2032-02-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Defined as time free of histologically proven recurrent T1-T4 recurrence, clinical evidence of nodal or distant metastasis, radical cystectomy (either for disease progression or due to toxicity), or death from any cause. Analysis will consist of estimation of the BIEFS curves via the Kaplan-Meier estimator and testing of the primary hypothesis using the stratified logrank test (one-sided). Additionally, the Cox proportional hazards model will be used to estimate the hazard ratio adjusting for stratification variables and any other baseline covariates that demonstrate any degree of imbalance by treatment arm.","measure":"Bladder intact event-free survival (BIEFS)","timeFrame":"Up to 5 years"},{"description":"Assessed using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) global quality of life domain.","measure":"Global quality of life","timeFrame":"Up to 5 years"}],"registered_date":{"date":"2025-01-13","type":"ACTUAL"},"registry_last_updated":"2026-11-09","registry_url":"https://clinicaltrials.gov/study/NCT06770582","short_name":"PARRC","short_name_basis":"canonical_name","sponsor":"National Cancer Institute (NCI)","start_date":{"date":"2025-06-03","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"NCI-2025-00008","type":"sponsor_study_id"},{"domain":"NRG Oncology; CTEP","id":"NRG-GU014","type":"other"},{"id":"U10CA180868","type":"nih"}],"study_type":"INTERVENTIONAL"}}}